---
title: "Kura Oncology Grants Stock Options to New Employees Under Inducement Plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275125150.md"
datetime: "2026-02-06T12:30:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275125150.md)
  - [en](https://longbridge.com/en/news/275125150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275125150.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275125150.md) | [繁體中文](https://longbridge.com/zh-HK/news/275125150.md)


# Kura Oncology Grants Stock Options to New Employees Under Inducement Plan

Kura Oncology Inc. has granted nonstatutory stock options to purchase 69,750 shares of common stock to four new employees under its 2023 Inducement Option Plan. Each option has an exercise price of $8.27 per share, reflecting the closing price of the company’s common stock on February 2, 2026. The options will vest over four years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remaining shares vesting monthly over the following 36 months, contingent on continued service with the company. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9649783) on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Kura Oncology, Inc. (KURA.US)](https://longbridge.com/en/quote/KURA.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook](https://longbridge.com/en/news/277979016.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/en/news/278556054.md)
- [Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | INTS Stock News](https://longbridge.com/en/news/278874097.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/en/news/278448836.md)
- [Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data](https://longbridge.com/en/news/278566951.md)